Title: | Process for Preparation of a Biomarker Specific for O-acetylated sialic acid Useful for Diagnosing, Monitoring Treatment Outcome, and Predicting Relapse of Lymphoblastic Leukemia |
Area: | Medical Sciences, Life Sciences & Biotechnology |
Focus Area: | Lymphoblastic Leukemia |
Patent: | IN191209 |
Social Benefits: | To provide a reagent, a novel biomarker specific for O-acety!ated sialic acid, by an simple process with a significant high yield. The reagent has an amplified biological potency to bind with cancer cells, therefore it has tremendous potential in terms of its detection capability of ALL patients under different phases of treatment eg. Potential for diagnosis and prognosis of ALL patients. Furthermore, the process for purification of a novel biomarker specific for O-acetylated sialic acid is not a complicated one and comprises only a few simple steps including removal of other non -O-acetylated proteins by using asialo bovine submaxillary mucin affinity column followed by capturing novel O-acetylated sialic acid specific biomarker using a bovine submaxillary mucin - Sepharose column. Thus a novel biomarker specific for O-acetylated sialic acid purified from these patients serum is of significant and maximum potency in detecting ALL patients under different phases of treatment i.e. detection of minimal residual disease in ALL, which is a challenging problem for leukemia specialist. To provide a reagent by a process" with a significant commercial application and can predict relapse. For diagnosis of ALL patients of different lineages e.g. T cell ALL, B cell ALL and mixed lineage ALL having cancer in both B and T lymphocytes by this novel biomarker specific for O-acetylated sialiclcid reflecting its general expression. It can distinguish between different stages of acute lymphoblastic leukemia which correlate well with the clinical status of the disease. It detects the extent to which the patient has responded to chemotherapy. Serum from other hematological disorder does not possess this biomarker Normal human serum contain very insignificant amount of this biomarker. |
Developing Agency: | CSIR-Indian Institute of Chemical Biology (IICB), West Bengal |
Technology Readiness Index: | Lab Validation |
Email: | director@iicb.res.in |
| Website Link : | http://www.iicb.res.in |
| Source (more info) : | https://t.ly/l_sb |